Israel says signed MOU with NRX Pharmaceuticals for COVID vaccine trials

Reuters|
PrintFind an error? Report us
Israel has signed a memorandum of understanding with NRX Pharmaceuticals to complete trials and commercialize the Israeli-developed COVID-19 vaccine BriLife, the Defense Ministry said on Monday.
The vaccine was developed by the Israel Institute for Biological Research, which is overseen by the Defense Ministry.
Comments
The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.
""